Seattle Genetics, Inc.

Rudolf Beier

Joachim Schuhmacher

Hans-Georg Lerchen

Karl-Heinz Thierauch

Beatrix Stelte-Ludwig

Simone Greven

Christoph Mahlert

Iring Heisler

Sherif El Sheikh

Sven Golfier

Lars Linden

Jörg Willuda

Axel Harrenga

Sandra Bruder

Hannah Jöriβen

Heike Petrul

Sandra Borkowski

The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Binder-drug conjugates (ADCs) and use thereof

Growing community of inventors

Berlin, Germany

Rudolf Beier